Moneycontrol
Last Updated : Dec 05, 2018 11:29 AM IST | Source: Moneycontrol.com

Alembic Pharma rises 3% on USFDA nod for drug to lower blood pressure

Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure.

Moneycontrol News @moneycontrolcom
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Shares of Alembic Pharmaceuticals rose 3 percent intraday Wednesday as company received USFDA approval for Candesartan Cilexetil Tablets.

The company has received approval from the US Food & Drug Administration (USFDA) for its abbreviated new drug application (ANDA) Candesartan Cilexetil tablets USP, 4 mg, 8 mg, and 16 mg.

The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Atacand tablets of ANI Pharmaceuticals, Irie.

Candesartan cilexetil tablets are indicated for the treatment of hypertension in adults and in children 1 to <17 years of age, to lower blood pressure.

Candesartan cilexetil tablets also indicated for the treatment of heart failure.

Candesartan Cilexetil Tablets USP have an estimated market size of USD 22 million for 12 months ending December 2017, according to IQVIA.

Alembic has a cumulative total of 82 ANDA approvals (69 final approvals and 13 tentative approvals) from USFDA.

At 11:22 hrs Alembic Pharmaceuticals was quoting at Rs 623.25, up Rs 8.20, or 1.33 percent on the BSE.

For more market news, click here

First Published on Dec 5, 2018 11:29 am
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant